PARP Inhibitor Activates the Intrinsic Pathway of Apoptosis in Primary Lung Cancer Cells

REFERENCES

• Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005;52(1):109–118.
   PubMed Web of Science ®Google Scholar
• Mark L, Katona A, Deli L. An attempt to evaluate the risk factors related to coronary heart disease in Hungary. Cor Vasa 1991;33(4):265–272.
   PubMedGoogle Scholar
• Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA, Windebank AJ. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One 2013;8(1):e54161.
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4(5): 421–440.
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013;34(6): 1217–1256.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011;10(8):1192–1199.
   PubMed Web of Science ®Google Scholar
• Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25(1):32–40.
   PubMed Web of Science ®Google Scholar
• Roux R, Zweifel M, Rustin GJ. Biologicals in the upfront treatment of ovarian cancer: focus on bevacizumab and poly (ADP-Ribose) polymerase inhibitors. Am Soc Clin Oncol Educ Book 2012;32:340–344.
   Google Scholar
• Lee YR, Yu DS, Liang YC, Huang KF, Chou SJ, Chen TC, Lee CC, Chen CL, Chiou SH, Huang HS. New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules. PLoS One 2013;8(2):e56284.
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013;73(7):2271–2280.
   PubMed Web of Science ®Google Scholar
• Spigel DR. PARP inhibitors in lung cancer. J Thorac Oncol 2012;7(16 Suppl 5):S392–S393.
   PubMedGoogle Scholar
• Nasuno T, Mimaki S, Okamoto M, Esumi H, Tsuchihara K. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci 2014;105(2): 202–210.
   PubMed Web of Science ®Google Scholar
• Sakogawa K, Aoki Y, Misumi K, Hamai Y, Emi M, Hihara J, Shi L, Kono K, Horikoshi Y, Sun J, Ikura T, Okada M, Tashiro S. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. Cancer Sci 2013;104(12):1593–1599.
   PubMed Web of Science ®Google Scholar
• Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G. PARP inhibitors in cancer therapy: magic bullets but moving targets. Front Oncol 2013;3:279.
   PubMedGoogle Scholar
• Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia 2013;15(10):1207–1217.
   PubMedGoogle Scholar
• Gangopadhyay NN, Luketich JD, Opest A, Visus C, Meyer EM, Landreneau R, Schuchert MJ. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest 2011;29(9):608–616.
   PubMed Web of Science ®Google Scholar
• Siegfried JM. Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line. J Cell Biochem 1989;41(2):91–95.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Watanabe T, Mondal A, Suzuki K, Kurusu-Kanno M, Li Z, Yamazaki T, Fujiki H, Suganuma M. Mechanism-based inhibition of cancer metastasis with (−)-epigallocatechin gallate. Biochem Biophys Res Commun 2014;443(1):1–6.
   PubMed Web of Science ®Google Scholar
• Tian T, Li J, Li B, Wang Y, Li M, Ma D, Wang X. Genistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cells. Tumour Biol 2014;35(5):4137–4145.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ 2009;16(1):3–11.
   PubMed Web of Science ®Google Scholar
• Yokosuka T, Goto H, Fujii H, Naruto T, Takeuchi M, Tanoshima R, Kato H, Yanagimachi M, Kajiwara R, Yokota S. Flow cytometric chemosensitivity assay using JC1, a sensor of mitochondrial transmembrane potential, in acute leukemia. Cancer Chemother Pharmacol 2013;72(6):1335–1342.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Bates SE. PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol Rep 2010;2.
   PubMedGoogle Scholar
• Shen Z, Huhn S. PTEN sumo-wrestles human RAD52 to mystery land. Cell Cycle 2013;12(23):3585.
   PubMed Web of Science ®Google Scholar
• Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013;11(2):140–148.
   PubMed Web of Science ®Google Scholar
• Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, Mufti GJ. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013;98(9):1397–1406.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D. Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007;98(10):1617–1624.
   PubMed Web of Science ®Google Scholar
• Linkov F, Gu Y, Arslan AA, Liu M, Shore RE, Velikokhatnaya L, Koenig KL, Toniolo P, Marrangoni A, Yurkovetsky Z, Zeleniuch-Jacquotte A, Lokshin AE. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. Eur Cytokine Netw 2009;20(1):21–26.
   PubMed Web of Science ®Google Scholar
• Bigbee WL, Gopalakrishnan V, Weissfeld JL, Wilson DO, Dacic S, Lokshin AE, Siegfried JM. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol 2012;7(4):698–708.
   PubMed Web of Science ®Google Scholar
• Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in Cancer. Front Oncol. 2013;3:290.
   PubMedGoogle Scholar
• Wu T, Wang XJ, Tian W, Jaramillo MC, Lau A, Zhang DD. Poly(ADP-ribose) polymerase-1 modulates Nrf2-dependent transcription. Free Radic Biol Med 2013;67C:69–80.
   Google Scholar
• Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer. 2010;9:45.
   PubMedGoogle Scholar
• Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras. Oncogene 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ausborn NL, Le QT, Bradley JD, Choy H, Dicker AP, Saha D, Simko J, Story MD, Torossian A, Lu B. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2012;83(4):e453–464.
   PubMed Web of Science ®Google Scholar
• Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene 2013;32(36):4231–4242.
   PubMed Web of Science ®Google Scholar
• Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999;274(33):22932–22940.
   PubMed Web of Science ®Google Scholar
• Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007;13(10):3033–3042.
   PubMed Web of Science ®Google Scholar
• Lapucci A, Pittelli M, Rapizzi E, Felici R, Moroni F, Chiarugi A. Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription. Mol Pharmacol 2011;79(6):932–940.
   PubMed Web of Science ®Google Scholar
• Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40(4):1117–1123.
   PubMed Web of Science ®Google Scholar
• Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58(23):5315–5320.
   PubMed Web of Science ®Google Scholar
• Suchy SL, Landreneau RJ, Schuchert MJ, Wang D, Ervin PR, Jr., Brower SL. Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer. Cancer Biol Ther 2013;14(1):39–44.
   PubMed Web of Science ®Google Scholar